AAP
VYGR icon

Arax Advisory Partners’s Voyager Therapeutics VYGR Stock Holding History

Arax Advisory Partners’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$185 Sell
48
-323
-87% -$1.27K ﹤0.01% 3554
2025
Q4 		$1.46K Sell
371
-1,253
-77% -$5.54K ﹤0.01% 3378
2025
Q3 		$7.58K Buy
+1,624
New +$5.88K ﹤0.01% 2715
2024
Q4 		– Sell
-411
Closed -$2.4K – 2770
2024
Q3 		$2.4K Hold
411
– – ﹤0.01% 1995
2024
Q2 		$3.25K Buy
+411
New +$3.45K ﹤0.01% 1791

Other funds holding VYGR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Arax Advisory Partners's VYGR Position: Q1 2026 in Review

Arax Advisory Partners reduced its Voyager Therapeutics (VYGR) stake by 87% in Q1 2026, selling an estimated $1.27K and leaving 48 shares worth $185. The position accounts for ﹤0.01% of the portfolio, ranked #3554.

Arax Advisory Partners first reported a position in VYGR in Q2 2024 and has held it in 5 quarters since. The position peaked at $7.58K in Q3 2025. 135 funds tracked by Wall St. Rank hold VYGR as of Q1 2026.

  • Arax Advisory Partners held 48 shares of Voyager Therapeutics worth $185 as of Q1 2026.
  • Arax Advisory Partners sold 323 Voyager Therapeutics shares in Q1 2026, an estimated $1.27K.
  • Voyager Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3554 holding.
  • Arax Advisory Partners first reported a position in Voyager Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • Arax Advisory Partners's Voyager Therapeutics position peaked at $7.58K in Q3 2025.
  • 135 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.